THE Therapeutic Goods Administration (TGA) presented on 'Clinical evidence and access for medicinal cannabis products' at the recent GP17 RACGP Conference, and has posted the presentation slide set on its website.
TGA's Pharmacovigilance and Special Access Branch principal medical adviser Dr Tony Gill presented the government's intent in terms of cannabis products, regulatory and access issues and the varying levels of evidence across different therapeutic uses including epilepsy, cancer and HIV induced nausea and vomitting, palliative care, multiple sclerosis as well as chronic and non-cancer pain - see tga.gov.au for more details.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Nov 17